{"name":"Tadashi Watabe","slug":"tadashi-watabe","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBPcUVJNlpQNjdlNm4waGh0QmVUa0RZU21pV1h2akJDeVRGd2xwRVEtM0JfaFJyLWNDaXdFbHRMLU05R0ljaHJnXzQxYVVnSWFUekxBMGRLYWF6QmZKSmp1TkxybmxRdw?oc=5","date":"2025-10-06","type":"pipeline","source":"大阪大学","summary":"Confirmed safety and effectiveness of new cancer treatment using astatine, a targeted α-therapy drug - 大阪大学","headline":"Confirmed safety and effectiveness of new cancer treatment using astatine, a targeted α-therapy drug - 大阪大学","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9SdVQxamNXZUgwY1M3emxuYVpSV2lwRGlGQVNSRWppS2s1TnNYVzVFdHlUQnY5SzVSdkVSdDdTaEIwNGJtVVdlNjBJb2VOVG1XdEk2cW1VUlgtRVNWWDBNckVjdmtGVGI2Ykh6WEpCVV9CNXB4X0g3bVNR?oc=5","date":"2025-09-25","type":"trial","source":"Journal of Nuclear Medicine","summary":"At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial) - Journal of Nuclear Medicine","headline":"At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNLXVsWGY4Y2pqN2lWaTJRblF6V3N6WV91TDlTNDFXTjNMQk9WN19IYWJQUzFnOWN3eHhqYlc1TVVkdF80OFJMYURlbV91dExQMlhNX0NlSG9sanFfV0RDd1gtOG45YWo1aW12aGFsQ09jQmlTS3lLNHAtc0ZFYXB2eFYweDVCMm1SeU5VQ0lFcjgwekhCSUVnLURjbUVfbHBmQzd2ZHJ0MGlGQkJhZVQ0MzJXZmwtaW9pdEVPQUdfdkZOSDRpZ1A2MVJibTdGckVscnhLTTgwa1M?oc=5","date":"2025-07-01","type":"pipeline","source":"BioPharma APAC","summary":"Alpha Fusion and Curadh Forge Joint Venture to Advance Astatine-211 Radiopharmaceuticals Globally - BioPharma APAC","headline":"Alpha Fusion and Curadh Forge Joint Venture to Advance Astatine-211 Radiopharmaceuticals Globally","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOVFZMRkJzNS1PRUJDdklKWThXZ1FnY2phM2lLMXZoQ3VlLXRyb0h5b1J3dUNEYVIySzhCQk91eWk4eTF4YVVhZlZSdElMT0VRMzlQYmt6NFFFbUFIdXVxYUZIWlI5Yk5rMnAwUXhBU2hmbEs3OG4wVi1rVkk2UGNMQWtLRF9YVnpreGdYSWxiTk5VeGpKSmloX3hXWTh1Slp0T3czcnV3?oc=5","date":"2025-03-13","type":"pipeline","source":"Lab Manager","summary":"New Metastatic Melanoma Treatment Uses Astatine-211 TAT - Lab Manager","headline":"New Metastatic Melanoma Treatment Uses Astatine-211 TAT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5LZEZ5TmJqeG85TUFEN2c4VHJIOVhuQURiR19lU1dhWXRHNlhTclJIMEhKdjhNSVZ4b0FhZ0xBVmpBMnZwVXlEaXhDSU56WVZINTM1dzEyaW1NU2xF?oc=5","date":"2025-03-12","type":"pipeline","source":"EurekAlert!","summary":"Targeted alpha therapy: a breakthrough in treating refractory skin cancer - EurekAlert!","headline":"Targeted alpha therapy: a breakthrough in treating refractory skin cancer - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBEMk5sS0dXRFc5a1hIZGVnWEhQS3hZMjNQSmVlQ29hcGYwRzNGWFBneHhwSHFpcndIYVREb2hfcC1WdXFDbzYxZnR3STFCWXZ3d09iOUtxcms2QQ?oc=5","date":"2023-10-12","type":"regulatory","source":"Journal of Nuclear Medicine","summary":"Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with - Journal of Nuclear Medicine","headline":"Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ua1NEZ1JmZU1CU3N3U0NGelgwQVptWUxWdEt4VDBKa3RLQzB0UFZvUER5X2ozbmpsTDBZUDMxdWdqVnYtZ25hUVpMSTNMVElLSnlETnRRbFphZkIxdVlZ?oc=5","date":"2021-06-21","type":"pipeline","source":"nature.com","summary":"At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution - nature.com","headline":"At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}